Literature DB >> 31350600

Blood Pressure and Statin Effects on Cognition: a Review.

Mia Yang1, Jeff Williamson2.   

Abstract

PURPOSE OF REVIEW: This is a review of available data on the effects of blood pressure and statins on cognition. RECENT
FINDINGS: Recent randomized clinical trials have shown that intensive control of systolic blood pressure in older adults prevented the development of mild cognitive impairment (MCI) and the combined effects of MCI and probable dementia. Previous randomized clinical trials have suggested that statin use may prevent a decline in cognition; however, no randomized clinical trials have clearly shown evidence of statin's either positive or negative effect on cognition. Continued follow-up of SPRINT-MIND participants is crucial to evaluate the long-term effects of intensive systolic blood pressure control on the prevention of cognitive decline. A well-conducted and adequately powered randomized control trial is needed to evaluate the effect of statins on cognition, especially for primary prevention of the cognitive decline in aging.

Entities:  

Keywords:  Blood pressure; Cognition; Cognitive impairment; Dementia; Hypertension; Statin

Mesh:

Substances:

Year:  2019        PMID: 31350600     DOI: 10.1007/s11906-019-0973-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  78 in total

1.  Primary prevention of cardiovascular disease: a call to action.

Authors:  Robert O Bonow
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Simvastatin-associated memory loss.

Authors:  A Orsi; O Sherman; Z Woldeselassie
Journal:  Pharmacotherapy       Date:  2001-06       Impact factor: 4.705

Review 3.  Cholesterol metabolism in the brain.

Authors:  J M Dietschy; S D Turley
Journal:  Curr Opin Lipidol       Date:  2001-04       Impact factor: 4.776

4.  Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease.

Authors:  Miia Kivipelto; Eeva-Liisa Helkala; Mikko P Laakso; Tuomo Hänninen; Merja Hallikainen; Kari Alhainen; Susan Iivonen; Arto Mannermaa; Jaakko Tuomilehto; Aulikki Nissinen; Hilkka Soininen
Journal:  Ann Intern Med       Date:  2002-08-06       Impact factor: 25.391

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 6.  Statin-associated memory loss: analysis of 60 case reports and review of the literature.

Authors:  Leslie R Wagstaff; Melinda W Mitton; Beth McLendon Arvik; P Murali Doraiswamy
Journal:  Pharmacotherapy       Date:  2003-07       Impact factor: 4.705

7.  APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein.

Authors:  K Chalmers; G K Wilcock; S Love
Journal:  Neuropathol Appl Neurobiol       Date:  2003-06       Impact factor: 8.090

8.  Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study.

Authors:  Zaldy Sy Tan; Sudha Seshadri; Alexa Beiser; Peter W F Wilson; Douglas P Kiel; Michael Tocco; Ralph B D'Agostino; Philip A Wolf
Journal:  Arch Intern Med       Date:  2003-05-12

9.  Low blood pressure and the risk of dementia in very old individuals.

Authors:  J Verghese; R B Lipton; C B Hall; G Kuslansky; M J Katz
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  2 in total

Review 1.  Statins and cognition: Modifying factors and possible underlying mechanisms.

Authors:  Tahereh Jamshidnejad-Tosaramandani; Soheila Kashanian; Mohamed H Al-Sabri; Daniela Kročianová; Laura E Clemensson; Mélissa Gentreau; Helgi B Schiöth
Journal:  Front Aging Neurosci       Date:  2022-08-15       Impact factor: 5.702

Review 2.  Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.

Authors:  Somin Kwon; Michiyo Iba; Changyoun Kim; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.